NVO
Novo Nordisk A/S
Healthcare · Drug Manufacturers - General · Denmark · Stock
Score Breakdown
Scored for Safe Long-Term Investing profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- The composite score of 60.2 is anchored by two perfect sub-scores — profitability at 20.0/20 and financial health at 20.0/20 — which together contribute 40 of a possible 40 points in those categories, reflecting exceptional fundamental quality from the 20-F filing data.
- The growth contribution of 10.0 and momentum of 9.0 add further meaningful weight, confirming that the business is expanding both on an annual and sequential basis as evidenced in the SEC EDGAR-sourced financials.
- The score did not reach the 70s or 80s primarily because the dividend (5.0) and theme (0.0) sub-scores together leave 35 points on the table compared to the maximum possible, holding the composite to the 60 range despite strong foundational metrics.
Why Not Higher
- The theme sub-score of 0.0 out of 20 is the single largest suppressor of the composite score — the model found no macro theme exposure tags applicable to Novo Nordisk's mapped filing data, which alone costs up to 20 points relative to a fully themed peer.
- The dividend sub-score of 5.0 out of 20 indicates that income-quality metrics such as FCF payout ratio, dividend per share growth CAGR, and FCF coverage do not rank in the upper tier within the model's dividend framework, preventing a higher aggregate score.
Data Confidence
9 / 10
Very High — full data coverage
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Novo Nordisk A/S is a Danish pharmaceutical company and one of the world's largest manufacturers of diabetes and obesity treatments, most notably its GLP-1 receptor agonist drugs including semaglutide-based products sold under brands such as Ozempic, Wegovy, and Rybelsus. The company files with the SEC as a foreign private issuer via Form 20-F and derives the vast majority of its revenue from its diabetes care and obesity care segments, with a growing international commercial footprint spanning North America, Europe, and international operations. Its research pipeline extends into rare blood disorders, cardiovascular disease, and emerging therapeutic areas. The model assigned NVO a score of 60.2/100, reflecting a mixed but fundamentally strong profile. The company earned perfect sub-scores in growth (10.0/20 mapped to a 10.0 contribution) and maximum sub-scores in both profitability (20.0/20) and financial health (20.0/20), signaling that its margins, return on assets, leverage ratios, and interest coverage are exceptionally robust by EDGAR filing standards. The momentum sub-score of 9.0 reflects continued sequential improvement in revenue and earnings across quarters, though not at the top tier. The dividend sub-score of 5.0 out of 20 is a relative drag, indicating moderate FCF payout characteristics or DPS growth that does not fully optimize for income-oriented scoring. Critically, the theme sub-score is 0.0, meaning the scoring model identified no macro theme exposure tags — a structural gap that prevents NVO from reaching higher composite scores under the current model version. The key research tradeoff for NVO is between its near-flawless fundamental quality — elite profitability, pristine balance sheet, and strong earnings growth — and the ceiling imposed by a zero theme score and a moderate dividend sub-score. For researchers focused on safe long-term investing, the model rates NVO as its best-fit profile at 71.0, confirming the fundamental quality argument, while speculative-profile researchers see the lowest fit at 52.2, consistent with NVO's very low risk rating and absence of high-risk/high-theme characteristics.
Plain English
Novo Nordisk is the Danish company behind Ozempic and Wegovy — the blockbuster diabetes and weight-loss drugs you've probably heard about. The model gives it a 60.2 out of 100, which is a solid but not top-tier score, mainly because its fundamentals like profits and balance sheet strength are outstanding, but a couple of scoring categories — dividend income metrics and macro theme tagging — pulled the total down. The Very Low risk rating means the filing data shows strong financial stability with low debt stress and high earnings coverage, making this a research candidate that fits conservative, long-term oriented analysis rather than a speculative growth play.
Bull Case vs. Bear Case
Bull Case
- Novo Nordisk earned a perfect profitability sub-score of 20.0/20, reflecting elite net margins, operating margins, and return on assets as derived from its FY2025 20-F filing — a level of profitability rarely achieved across global pharmaceutical peers.
- The financial health sub-score of 20.0/20 indicates that the company's leverage ratios, interest coverage, and overall balance sheet structure are at the strongest end of the model's range, providing significant financial resilience even in adverse operating environments.
- A growth sub-score of 10.0 confirms meaningful year-over-year expansion in revenue, net income, and earnings per share as reported in the EDGAR filings, consistent with continued commercial scaling of its GLP-1 portfolio across diabetes and obesity care.
Bear Case
- The dividend sub-score of only 5.0 out of 20 suggests that Novo Nordisk's FCF payout ratio, DPS growth consistency, or dividend coverage metrics do not rank strongly within the model, limiting its appeal as a high-conviction income research candidate.
- The theme sub-score of 0.0 out of 20 means the scoring model found no qualifying macro theme exposures in the mapped filing data, which structurally caps the composite score and may reflect a gap in diversification across emerging technology or structural growth themes.
- The momentum sub-score of 9.0 out of 20, while positive, indicates that sequential quarterly improvements in revenue, earnings, and margins — as extracted from the 20-F — are present but not accelerating at a rate that would merit a top-tier momentum reading.
What Could Change the Picture
Bullish Triggers
- An improvement in the dividend sub-score — driven by filing-evidenced acceleration in DPS growth CAGR, a more favorable FCF payout ratio, or a longer consecutive DPS streak — would directly lift the composite score and strengthen the income-quality research case.
- If subsequent model versions incorporate macro theme tagging for GLP-1 drug adoption, obesity therapeutics, or cardiometabolic disease as qualifying themes, NVO's theme sub-score could rise from 0.0 toward a meaningful contributor, materially increasing the composite score.
Bearish Triggers
- A material deterioration in the profitability sub-score — such as margin compression from pricing pressure, increased R&D spend, or competitive entry reducing net margins as reflected in future 20-F filings — would directly erode the 20.0/20 profitability contribution that underpins the current score.
- A weakening of the financial health sub-score driven by rising leverage, declining interest coverage, or balance sheet deterioration from large-scale acquisitions or debt issuance would undermine the current 20.0/20 rating and raise the overall risk profile above its current Very Low designation.
Red Flags
- The dividend sub-score of 5.0/20 warrants monitoring: if FCF payout ratios are elevated or DPS growth is slowing relative to earnings growth, this could signal that capital return priorities are shifting or that free cash flow conversion is under pressure.
Risk Profile
Very Low RiskThe Very Low risk rating for Novo Nordisk reflects filing-derived evidence of minimal financial leverage stress, strong interest coverage, and consistent earnings generation, all of which the model interprets as indicators of balance sheet and income stability rather than volatility. For a foreign private issuer of this size and profitability profile, the combination of elite financial health and profitability sub-scores is consistent with a company that poses limited fundamental financial risk as measured by the EDGAR filing data.
Key Catalysts to Watch
The key factors to monitor from a filing-data perspective include the trajectory of revenue and earnings growth in future 20-F filings — particularly whether the growth sub-score sustains or improves as GLP-1 product lines scale — and whether capital allocation decisions shift the dividend sub-score meaningfully, as this remains the clearest lever for composite score improvement within the current model framework.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.